Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

10-06-2021 | ASCO 2021 | Conference coverage | Video

Genitourinary cancers: Clinical insights into trial data

Editorial board member Axel Merseburger discusses the clinical implications of key genitourinary cancer abstracts presented at the 2021 ASCO Annual Meeting, including the KEYNOTE-564 and VISION trials, as well as brain metastases data from CheckMate 920 and updates on several enfortumab vedotin studies (6:40).

00:00 - Introduction
00:29 - Renal cell cancer studies
03:04 - Prostate cancer studies
04:12 - Bladder cancer studies

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

04-06-2021 | ASCO 2021 | Conference coverage | News

KEYNOTE-564 supports adjuvant pembrolizumab use in high-risk RCC patients

04-06-2021 | ASCO 2021 | Conference coverage | News

VISION: LuPSMA addition improves pretreated mCRPC survival

07-06-2021 | ASCO 2021 | Conference coverage | News

CANTATA: No improvement in advanced RCC outcomes with telaglenastat addition
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits